Login to your account
Don’t have an account?
Create a Free Account
The Lancet Microbe Homepage
FEATURE
“Brains are usually drained from places, not whole areas of research, and such brain drain from a fundamental field in modern medicine is concerning.”
Read more
-
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study
Patients admitted to hospital with less favourable 5-day biomarker trajectories had worse prognosis, suggesting that persistent viral burden might drive inflammation in the pathogenesis of COVID-19, identifying patients that might benefit from escalation of antiviral or anti-inflammatory treatment. -
Importance of investing time and money in integrating large language model-based agents into outbreak analytics pipelines
Outbreaks such as mpox and COVID-19 underscore the need for swift, evidence-based responses to limit their spread and save lives. Such evidence should be generated in real time. Generating these insights requires synthesis of many different sources of information and a combination of multiple distinct analytical techniques, from basic descriptive analysis to complex dynamic models.1 Timely generation of policy-relevant evidence relies on skilled staff and prebuilt outbreak analytics pipelines, alongside rapid literature reviews and ad-hoc data curation processes. -
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
SpFN/ALFQ was well tolerated and elicited robust and durable binding antibody and neutralising antibody titres against a broad panel of SARS-CoV-2 variants and other sarbecoviruses. -
Plasmodium ovale spp dhfr mutations associated with reduced susceptibility to pyrimethamine in sub-Saharan Africa: a retrospective genetic epidemiology and functional study
The widespread use of sulfadoxine–pyrimethamine for malaria chemoprevention might have exerted fortuitous selection pressure for dhfr mutations in P ovale spp. This calls for closer monitoring of dhfr and dhps mutations in P ovale spp.
Audio View More
Equity, diversity, and inclusion: Advancing equity, diversity, and inclusion (EDI) is a commitment to health for all. Find out more about how we are advancing EDI in the work that we publish, our editorial policies, and our own workforce.
-
Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study
Our study demonstrates potent protective immunity induced by homologous vaccination and homologous or heterologous previous SARS-CoV-2 infection. The community breakthrough infections seen with the omicron variant supports the use of newer variants to establish a model with sufficient rate of infection for use in vaccine and therapeutic development. -
SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial
SpFN/ALFQ was well tolerated and elicited robust and durable binding antibody and neutralising antibody titres against a broad panel of SARS-CoV-2 variants and other sarbecoviruses. -
The 2023 WHO World malaria report
The estimated number of global malaria cases in 2022 exceeded pre-COVID-19 pandemic levels in 2019, according to WHO’s 2023 World malaria report . Several threats to the malaria global response are highlighted in the report, including climate change. -
Blood transcriptomic analyses reveal persistent SARS-CoV-2 RNA and candidate biomarkers in post-COVID-19 condition
With an estimated 65 million individuals affected by post-COVID-19 condition (also known as long COVID),1 non-invasive biomarkers are direly needed to guide clinical management. To address this pressing need, we used blood transcriptomics in a general practice-based case-control study. Individuals with long COVID were diagnosed according to WHO criteria, and validated clinical scales were used to quantify patient-reported outcomes.2 Whole blood samples were collected from 48 individuals with long COVID and 12 control individuals matched for age, sex, time since acute COVID-19, severity, vaccination status, and comorbidities (appendix 1 p 2).